Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth. Celecoxib may slow the growth of cancer by stopping blood flow to the
tumor. Combining gefitinib with celecoxib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining gefitinib with celecoxib in
treating patients who have non-small cell lung cancer that is refractory to platinum-based
chemotherapy (such as cisplatin or carboplatin).